{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T15:49:20Z","timestamp":1773071360853,"version":"3.50.1"},"reference-count":10,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T00:00:00Z","timestamp":1482969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["219770"],"award-info":[{"award-number":["219770"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The purpose of the present trial was to evaluate safety, tolerability, and effect on systolic blood pressure (SBP) of SER100 in a small group of patients with isolated systolic hypertension (ISH) in treatment with at least 1 antihypertensive drug. Eligible patients were randomized to either SER100 (10 mg) or placebo in a crossover design, and 2 doses were given subcutaneously (SC), 8 hours apart, on 2 consecutive days. On all treatment days patients were monitored with an ambulatory blood pressure measurement device for 12 daytime hours. Seventeen patients completed treatment. There were no serious or severe adverse events. Relative to placebo SER100 induced an average reduction of SBP during the 2 treatment days of 7.0 mm Hg (<jats:italic>P<\/jats:italic> = 0.0032), whereas the average reduction of diastolic blood pressure (DBP) over the same period was 3.8 mm Hg (<jats:italic>P<\/jats:italic> = 0.0011). For patients with ISH, this short\u2010term cross\u2010over study of SC SER100 demonstrated an acceptable safety profile and consistent, significant lowering of SBP and DBP. As initial clinical proof of concept for a new class of drugs, a nociceptin agonist peptide, the results were encouraging and warrant further research.<\/jats:p>","DOI":"10.1002\/cpdd.330","type":"journal-article","created":{"date-parts":[[2016,12,29]],"date-time":"2016-12-29T06:57:09Z","timestamp":1482994629000},"page":"584-591","source":"Crossref","is-referenced-by-count":14,"title":["Safety, Tolerability, and Antihypertensive Effect of SER100, an Opiate Receptor\u2010Like 1 (ORL\u20101) Partial Agonist, in Patients With Isolated Systolic Hypertension"],"prefix":"10.1002","volume":"6","author":[{"given":"Ilkka","family":"Kantola","sequence":"first","affiliation":[{"name":"Division of Medicine Turku University Hospital  Turku Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Scheinin","sequence":"additional","affiliation":[{"name":"CRST Ltd  It\u00e4inen Pitk\u00e4katu Turku Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trygve","family":"Gulbrandsen","sequence":"additional","affiliation":[{"name":"Serodus ASA  Gaustadalleen Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils","family":"Meland","sequence":"additional","affiliation":[{"name":"Smerud Medical Research International AS  Karenslyst alle Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Knut T.","family":"Smerud","sequence":"additional","affiliation":[{"name":"Smerud Medical Research International AS  Karenslyst alle Oslo Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,12,29]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2572"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703219"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945007779315605"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704894"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.083436"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707688"},{"key":"e_1_2_10_8_1","article-title":"Dose\u2010dependent pharmacokinetics of the novel peptide aquaretic, ZP120 in both humans and rats","author":"Knudsen CB","year":"2005","journal-title":"American Association of Pharmaceutical Scientists"},{"key":"e_1_2_10_9_1","doi-asserted-by":"crossref","unstructured":"FischettiC RizziA GavioliEC et\u00a0al.Further studies on the pharmacological features of the nociceptin\/orphanin FQ receptor ligand ZP120.Peptides.2009;30:248\u2010255.","DOI":"10.1016\/j.peptides.2008.10.001"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00329.2003"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MBP.0b013e32833531ca"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.330","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.330","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.330","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T04:14:41Z","timestamp":1695701681000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,29]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/cpdd.330"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.330","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,29]]}}}